Tag: global chronic liver diseases therapeutics market

  • Chronic Liver Diseases Therapeutics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Chronic Liver Diseases Therapeutics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    How Are Key Drivers Contributing to the Growth and Expansion of the Chronic Liver Diseases Therapeutics Market?

    The increasing alcohol consumption is expected to drive the growth of the chronic liver disease therapeutics market. Alcohol consumption, which has grown due to increasing social acceptance, higher incomes, and broader accessibility, is a major risk factor for liver diseases, including chronic liver disease. Therapeutics for chronic liver disease help manage liver damage caused by excessive alcohol intake and slow disease progression. For instance, in June 2024, First Citizens Bank reported a 1.2% increase in wine sales, and Kirin Holdings Company reported a 2.9% increase in global beer consumption in 2022, signaling the growing alcohol consumption trends. As alcohol consumption rises, the demand for chronic liver disease therapeutics is expected to grow accordingly.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp

    #What Long-Term Growth Rate is Expected for theChronic Liver Diseases Therapeutics Market Between 2025 and 2034?

    The chronic liver disease therapeutics market has expanded rapidly, forecasted to grow from $14.38 billion in 2024 to $15.92 billion in 2025, reflecting a CAGR of 10.7%. Factors contributing to past growth include a rising incidence of viral hepatitis, increasing obesity rates, an aging population, growing awareness of liver health, and greater patient access to treatment.

    The chronic liver disease therapeutics market is set for rapid expansion, projected to grow to $23.83 billion by 2029 at a CAGR of 10.6%. Growth drivers include a greater emphasis on personalized medicine, an increasing pipeline of novel therapies, the rise of telemedicine and digital health solutions, growing demand for liver disease prevention programs, and a higher incidence of viral hepatitis. Key trends in this field involve the incorporation of artificial intelligence in diagnostics, advancements in biologics and gene therapies, non-invasive treatment alternatives, combination therapies, and the shift toward patient-centric care models.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145

    What New Market Trends Are Reshaping theChronic Liver Diseases Therapeutics Market and Its Opportunities?

    In the chronic liver diseases therapeutics market, companies are focused on developing advanced treatments such as RNA therapies to target genetic and molecular mechanisms, offering more effective and personalized treatment options. RNA therapies are advanced medical treatments that utilize RNA molecules to regulate gene expression or protein production to treat or prevent diseases. For example, in May 2022, Ochre Bio, a UK-based biotech company, opened its innovative ‘Liver ICU’ research facility at BioLabs@NYULangone in New York City. This state-of-the-art site assesses the effectiveness of next-generation RNA therapeutics using whole human livers sustained on perfusion machines, with the goal of accelerating drug development and improving liver treatment precision by replicating human physiological conditions.

    Who Are the Leading Market Players Fueling Growth in the Chronic Liver Diseases Therapeutics Market Trend?

    Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/chronic-liver-diseases-therapeutics-global-market-report

    How is the Global Chronic Liver Diseases Therapeutics Market Segemented?

    The chronic liver diseases therapeutics market covered in this report is segmented –

    1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy

    2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders

    3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals

    2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors

    3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines

    4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin

    5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone

    6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies

    7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=21145&type=smp

    Which Geographics are Influencing the Growth of the Chronic Liver Diseases Therapeutics Market?

    North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Chronic Liver Diseases Therapeutics Market 2025, By The Business Research Company:

    Urothelial Carcinoma Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

    Mineral And Bone Disorder Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

    Pancreatic Cancer Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Chronic Liver Diseases Therapeutics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Chronic Liver Diseases Therapeutics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    How Are Key Drivers Contributing to the Growth and Expansion of the Chronic Liver Diseases Therapeutics Market?

    The increasing alcohol consumption is expected to drive the growth of the chronic liver disease therapeutics market. Alcohol consumption, which has grown due to increasing social acceptance, higher incomes, and broader accessibility, is a major risk factor for liver diseases, including chronic liver disease. Therapeutics for chronic liver disease help manage liver damage caused by excessive alcohol intake and slow disease progression. For instance, in June 2024, First Citizens Bank reported a 1.2% increase in wine sales, and Kirin Holdings Company reported a 2.9% increase in global beer consumption in 2022, signaling the growing alcohol consumption trends. As alcohol consumption rises, the demand for chronic liver disease therapeutics is expected to grow accordingly.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp

    #What Long-Term Growth Rate is Expected for theChronic Liver Diseases Therapeutics Market Between 2025 and 2034?

    The chronic liver disease therapeutics market has expanded rapidly, forecasted to grow from $14.38 billion in 2024 to $15.92 billion in 2025, reflecting a CAGR of 10.7%. Factors contributing to past growth include a rising incidence of viral hepatitis, increasing obesity rates, an aging population, growing awareness of liver health, and greater patient access to treatment.

    The chronic liver disease therapeutics market is set for rapid expansion, projected to grow to $23.83 billion by 2029 at a CAGR of 10.6%. Growth drivers include a greater emphasis on personalized medicine, an increasing pipeline of novel therapies, the rise of telemedicine and digital health solutions, growing demand for liver disease prevention programs, and a higher incidence of viral hepatitis. Key trends in this field involve the incorporation of artificial intelligence in diagnostics, advancements in biologics and gene therapies, non-invasive treatment alternatives, combination therapies, and the shift toward patient-centric care models.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145

    What New Market Trends Are Reshaping theChronic Liver Diseases Therapeutics Market and Its Opportunities?

    In the chronic liver diseases therapeutics market, companies are focused on developing advanced treatments such as RNA therapies to target genetic and molecular mechanisms, offering more effective and personalized treatment options. RNA therapies are advanced medical treatments that utilize RNA molecules to regulate gene expression or protein production to treat or prevent diseases. For example, in May 2022, Ochre Bio, a UK-based biotech company, opened its innovative ‘Liver ICU’ research facility at BioLabs@NYULangone in New York City. This state-of-the-art site assesses the effectiveness of next-generation RNA therapeutics using whole human livers sustained on perfusion machines, with the goal of accelerating drug development and improving liver treatment precision by replicating human physiological conditions.

    Who Are the Leading Market Players Fueling Growth in the Chronic Liver Diseases Therapeutics Market Trend?

    Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/chronic-liver-diseases-therapeutics-global-market-report

    How is the Global Chronic Liver Diseases Therapeutics Market Segemented?

    The chronic liver diseases therapeutics market covered in this report is segmented –

    1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy

    2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders

    3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals

    2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors

    3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines

    4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin

    5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone

    6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies

    7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=21145&type=smp

    Which Geographics are Influencing the Growth of the Chronic Liver Diseases Therapeutics Market?

    North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Chronic Liver Diseases Therapeutics Market 2025, By The Business Research Company:

    Urothelial Carcinoma Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

    Mineral And Bone Disorder Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

    Pancreatic Cancer Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Chronic Liver Diseases Therapeutics Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

    Chronic Liver Diseases Therapeutics Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

    Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

    How has the chronic liver diseases therapeutics market grown in recent years?

    The market size for therapeutics pertaining to chronic liver disease has experienced significant expansion in the recent past. The market, which was valued at $14.38 billion in 2024, is expected to elevate to $15.92 billion in 2025, showing a compound annual growth rate (CAGR) of 10.7%. The historical growth in this market can be attributed to factors such as the escalations in cases of viral hepatitis, elevated rates of obesity, demographics shifting towards an aging population, increased cognizance surrounding liver health, and enhanced accessibility to treatment for patients.

    How is the chronic liver diseases therapeutics market size expected to evolve during the forecast period?

    The market for therapeutics for chronic liver disease is projected to experience swift expansion in the coming years, expected to reach a valuation of $23.83 billion in 2029, growing at a compound annual growth rate of 10.6%. This growth can be attributed to an increased emphasis on personalised medicine, a growing range of innovative therapies in the pipeline, and an expansion of telemedicine and digital health solutions. Other factors include a heightened demand for liver disease prevention initiatives and growing incidence of viral hepatitis. Notable trends include the incorporation of artificial intelligence in diagnostics, the advancements in gene and biologic therapies, the development of non-invasive treatment methods, the application of combination therapies, and the broadening of patient-centric care models.

    Get your chronic liver diseases therapeutics market report here!

    https://www.thebusinessresearchcompany.com/report/chronic-liver-diseases-therapeutics-global-market-report

    Which key drivers are propelling the chronic liver diseases therapeutics market’s growth?

    The rise in alcohol consumption is anticipated to boost the advancement of the market for therapeutic treatment of chronic liver disease. Drinking alcoholic beverages, which contain ethanol, can vary from moderate to excessive use and may affect health. The growth in alcohol use is attributed to its increased social acceptability, higher income levels, and improved accessibility worldwide. Therapies for chronic liver disease aim to manage liver damage triggered by excessive alcohol consumption, decelerating disease advancement and enhancing liver function. It is worth mentioning, for example, that as per the First Citizens Bank, a financial institution based in the US, there was a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022, in June 2024. Also, in December 2023, a report from Kirin Holdings Company Limited, a Japanese beverage company, disclosed that approximately 192.1 million kiloliters of beer were consumed in 2022, showing a 2.9% increase from the previous year. Consequently, the growing consumption of alcohol is fueling the expansion of the market for chronic liver disease therapeutics.

    What are the market segments in the chronic liver diseases therapeutics industry?

    The chronic liver diseases therapeutics market covered in this report is segmented –

    1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy

    2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders

    3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals

    2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors

    3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines

    4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin

    5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone

    6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies

    7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp

    Which leading companies are shaping the growth of the chronic liver diseases therapeutics market?

    Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

    What are the key trends shaping the future of the chronic liver diseases therapeutics market?

    Key players in the therapeutics market for chronic liver diseases are concentrating on creating advancements like RNA therapies that aim at genetic and molecular mechanisms, providing more efficient and customized treatment choices. RNA therapies, modern medical treatments that use RNA molecules to control gene expression or protein creation, work towards treating or preventing diseases by focusing on particular genetic mechanisms. For example, Ochre Bio, a biotech firm based in the UK, initiated their groundbreaking ‘Liver ICU’ research facility at BioLabs@NYULangone, a biopharmaceutical incubator located in New York City, in May 2022. This cutting-edge site evaluates the potency of next-gen RNA therapeutics by utilizing whole human livers maintained on perfusion devices. The facility’s goal is to expedite the drug development process and enhance the accuracy of liver treatment studies by imitating human physiological states, using rejected donor livers for research purposes.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145

    Which geographic areas are influencing the growth of the chronic liver diseases therapeutics market?

    North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Urothelial Carcinoma Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

    Mineral And Bone Disorder Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

    Pancreatic Cancer Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • How Will the Chronic Liver Diseases Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond

    How Will the Chronic Liver Diseases Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How Will the Chronic Liver Diseases Therapeutics Market Grow Over the Forecast Period Based on Its Expected CAGR?

    The market size for therapeutics of chronic liver disease has seen a swift expansion in the past few years. It is projected to escalate from $14.38 billion in 2024 to $15.92 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.7%. Factors such as heightened instances of viral hepatitis, rising obesity rates, an aging populace, growing cognizance of liver health, and wider patient access to appropriate treatments have contributed to this growth rate during the historical period.

    The projected expansion for the chronic liver disease therapeutics market is predicted to balloon at a significant pace in the upcoming years, pushing its worth to $23.83 billion in 2029 and posting a compound annual growth rate (CAGR) of 10.6%. The uplift in forecast is attributed to several elements – enhanced adoption of personalized medicine, the development of new, innovative treatments, an increase in telemedicine and digital health solutions, and the heightened need for liver disease prevention schemes, alongside the surging cases of viral hepatitis. Key trends emerging in the market include the integration of AI in diagnosis, the use of biologics and gene therapies, non-invasive treatments, combined therapies, and the broadening of patient-focused care models.

    What Factors Are Propelling the Growth of the Chronic Liver Diseases Therapeutics Market from 2025 to 2034?

    The chronic liver disease therapeutics market’s growth is anticipated to be driven by the rise in alcohol consumption. Ethanol-containing beverages, also known as alcohol, is consumed in varying degrees, from moderate to excessive, which can potentially affect health. The escalation in drinking alcohol can be attributed to its growing social acceptance, surging incomes, and increased availability across the globe. Therapeutics for chronic liver disease are used to control liver damage resulting from high alcohol consumption, slowing the progression of the disease and enhancing liver function. For example, the First Citizens Bank, a US-based financial institution, reported in June 2024 that a 1.2% surge in direct-to-consumer (DTC) wine case sales occurred in 2023 compared to 2022. Furthermore, the Kirin Holdings Company Limited, a beverage company based in Japan, published a report in December 2023 indicating that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% rise from the previous year. Consequently, the upsurge in alcohol consumption is fueling the expansion of the chronic liver disease therapeutics market.

    Get Your Free Sample of the Global Chronic Liver Diseases Therapeutics Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp

    Who Are the Dominant Players Expanding Their Reach in the Chronic Liver Diseases Therapeutics Market?

    Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

    What Are the Top Trends Shaping the Evolution of the Chronic Liver Diseases Therapeutics Market?

    Leading enterprises in the chronic liver diseases therapeutics market are concentrating on the development of innovative solutions, such as RNA therapies, which target fundamental genetic and molecular mechanisms, thereby providing more efficient and personalized treatment options. RNA therapies employ RNA molecules to control gene expression or protein synthesis with an objective to prevent or treat diseases by targeting unique genetic mechanisms. For instance, in May 2022, Ochre Bio, a biotechnological firm based in the UK, introduced its revolutionary research facility called ‘Liver ICU’ at BioLabs@NYULangone, a biopharmaceutical incubator located in New York City. This advanced site evaluates the effectiveness of next-generation RNA therapeutics by using entire human livers maintained on perfusion machines. The facility aims to expedite the drug development process and enhance the accuracy of liver treatment studies by mimicking human physiological conditions, utilizing discarded donor livers for research.

    Get Instant Access to the Global Chronic Liver Diseases Therapeutics Market Report with Swift Delivery!

    https://www.thebusinessresearchcompany.com/report/chronic-liver-diseases-therapeutics-global-market-report

    Which Market Segments Are Driving Strategic Growth and Trends in the Chronic Liver Diseases Therapeutics Market?

    The chronic liver diseases therapeutics market covered in this report is segmented –

    1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy

    2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders

    3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals

    2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors

    3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines

    4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin

    5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone

    6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies

    7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents

    Which Regions Are Setting the Pace for Chronic Liver Diseases Therapeutics Market Growth?

    North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    How Is the Chronic Liver Diseases Therapeutics Market Defined Across Different Regions?

    Chronic liver disease therapeutics refers to the medical treatments and interventions aimed at managing long-term liver conditions. These therapies focus on slowing disease progression, alleviating symptoms, and improving liver function through medications, lifestyle changes, and, in some cases, advanced procedures.

    Browse Through More Similar Reports By The Business Research Company:

    Urothelial Carcinoma Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

    Mineral And Bone Disorder Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

    Pancreatic Cancer Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: